Meanings
- uncountablemedicineA bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer.
Pasotuxizumab (AMG 212) is a canonical BiTE antibody targeting PSMA [77]. The anti-tumor activity which was defined by PSA level decrease was dose-dependent. Two patients achieved long-term PSA responses with more than 1 year of treatment at doses of 40 μg/d and 80 μg/d, respectively.
2021 May 26, Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu, “The landscape of bispecific T cell engager in cancer treatment”, in Biomarker Research, volume 9, →DOI, article 38, page 4
Origin
From [Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”).
Full word history & related roots →Cite this entry
pasotuxizumab. (n.d.). In WatkinsX Dictionary. Retrieved November 4, 2026, from https://dictionary.watkinsx.com/word/pasotuxizumab
“pasotuxizumab.” WatkinsX Dictionary, https://dictionary.watkinsx.com/word/pasotuxizumab. Accessed November 4, 2026.
WatkinsX Dictionary, s.v. “pasotuxizumab,” accessed November 4, 2026, https://dictionary.watkinsx.com/word/pasotuxizumab.
Source: pasotuxizumab on Wiktionary, CC BY-SA 4.0.